Prelude Therapeutics Cuts Quarterly Net Loss 55% As R&D Spending Falls 38%
By Amit Chowdhry ● Aug 22, 2026
Prelude Therapeutics reduced its second-quarter 2026 net loss by approximately 55% year-over-year as research and development spending declined sharply following the pausing of previous clinical programs and a workforce reduction. Net loss narrowed to $13.9 million, or $0.14 per share, from $31.2 million, or $0.41 per share, in the prior-year quarter.